Composition and therapeutic anti-tumour vaccine
US10780151B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 24, 2018 |
| Grant date | Sep 22, 2020 |
| Priority date | — |
| Expiry date | May 26, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/6056
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a composition which induces, in a host, a cytotoxic cell response directed against cells expressing an antigen, in particular tumour cells, and which comprises red blood cells containing said antigen. These red blood cells may be in the form of an immune complex with an immunoglobulin, in particular IgG, which recognizes an epitope at the surface of the red blood cells, and/or be heat-treated or chemically treated so as to promote phagocytosis of said red blood cells by dendritic cells. As a variant, the red blood cells may be xenogenic red blood cells. The invention also relates to a therapeutic especially anti-tumour vaccine containing such a composition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.